Merck CEO makes pitch to investors touting refocused drug maker
This article was originally published in Scrip
Merck & Co will decide by the end of the year whether to shed its animal health and consumer businesses, part of a plan to refocus the big US drug maker.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.